Mental health is one of Elion’s areas of expertise. This week we’ve found industry news highlighting promising therapies for Alzheimer’s and schizophrenia, as well as a caution about commenting on social media.
Independent advisors to the FDA have unanimously agreed that Leqembi, an Alzheimer’s drug being developed by Eisai-Biogen, benefits patients.
Leqembi is an amyloid beta-directed antibody given via an intravenous infusion and was initially granted an accelerated approval in January based on a phase II study demonstrating it helped reduce amyloid plaques. The panel voted unanimously to confirm the clinical benefit of Leqembi based on a phase III trial demonstrating it slowed clinical and functional decline by 27% compared with placebo at 18 months. It is now expected that Leqembi will be the first of its class to get full approval.
Cardiff University has begun a study of schizophrenia therapy. MDI-26478 is a positive allosteric modulator of the AMPA receptor which is thought to play an important role in brain health.
MDI-26478 has completed the first phase of a phase one clinical trial. It has been demonstrated to be safe at all doses, with Cardiff University’s Medicines Discovery Institute progressing with the remainder of the study.
Here’s a good reminder of what to watch out for when posting or reacting on social media platforms. AstraZeneca has breached marketing rules with LinkedIn post engagement but has avoided a serious code breach.
An employee of AstraZeneca UK liked and commented on a post from an academic researcher about the PRESERVED-HF trial about Forxiga. The Prescription Medicines Code of Practice Authority (PMCPA) found AstraZeneca breached three PMCPA clauses and AstraZeneca’s own social media policy.
Elion Medical Communications has a wide body of experience in mental health therapies. Visit elion.nz to find out more about what we offer
